Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Immunophenotyping in Patients With Osteoporosis

Immunological Markers for the Improvement of Diagnosis and Therapy of Osteoporosis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

In addition to a medical history and clinical examination, the diagnosis of osteoporosis includes the measurement of bone surface density by means of dual X-ray absorptiometry (DXA). In addition, blood tests are performed for certain parameters, such as vitamin D, calcium, phosphate and C-reactive protein. In order to optimize osteoporosis diagnostics, the development of further specific methods is required. The modulation of the immune system seems promising in this respect, since osteoporosis is based on an inflammatory reaction. Various regulatory markers of the innate and acquired immune system, which seem to be relevant in the development of the disease, have already been detected in osteoporosis patients. This study may help to gain new insights into disease-associated immunoregulatory markers that could revolutionize both the diagnosis and therapy of osteoporosis in the long term. By means of a simple blood test, patients could be diagnosed early and without additional radiation exposure, and effective therapy options could be developed.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult patients (≥ 18 years) diagnosed with osteoporosis. - Written willing to sign a consent form from the patient Who Should NOT Join This Trial: - Patients without diagnosed osteoporosis - Patients without written willing to sign a consent form - Patients \< 18 years old - Patients with secondary osteoporosis Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adult patients (≥ 18 years) diagnosed with osteoporosis. * Written informed consent from the patient Exclusion Criteria: * Patients without diagnosed osteoporosis * Patients without written informed consent * Patients \< 18 years old * Patients with secondary osteoporosis

Treatments Being Tested

DIAGNOSTIC_TEST

Immunological markers

Markers of blood samples of patients suffering from osteoporosis will be analyzed

Locations (1)

University Hospital of Bonn
Bonn, Northrhine Westfalia, Germany